Press Release

August 5, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026. We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026 Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Investor Relations | Corporate Communications Press Release Phone: 040-66721211 Email: ir@aurobindo.com Hyderabad, India, August 05th, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2026. Aurobindo Pharma Limited Q1FY27 Amount (INR Cr) Q1FY27 Q1FY26 Q4FY26 Change YoY Change QoQ Revenue from Operations 9,150 7,868 16.3% 8,853 3.4% EBITDA before R&D 2,208 1,947 13.4% 2,165 2.0% EBITDA margin before R&D 24.1% 24.8% -63 bps 24.5% -33 bps EBITDA (Before Forex and Other Income and 1,924* 1,603 20.0% 1,801 6.8% exceptional items) EBITDA Margin (%) 21.0% 20.4% 60 bps 20.3% 69 bps PBT before share of P/L of JV 1,517 1,205 25.9% 1,293 17.3% Net Profit for the period 1,032 824 25.2% 921 12.1% *Operating EBITDA excluding one time impact of ₹43 cr on account of derecognition of lease receivable Key Highlights of Q1FY27 • Revenue from Operations increased by 16.3% YoY to INR 9,150 Cr with growth across businesses • US revenue increased by 8.1% YoY to INR 3,770 Cr (USD 399 million) • Europe revenue increased by 25.6% YoY to INR 2,937 Cr (EUR 267 million) • Growth Markets revenue increased by 37.7% YoY to INR 1,063 Cr (USD 113 million) • ARV revenue for the quarter stood at INR 330 Cr (USD 35 million) • Received final approval for 10 products from USFDA • Net Profit for the quarter stood at INR 1,032 Cr • Strong net cash position (including investments) stood at USD 42mn as on 30-Jun-26 (after payment of Lannett acquisition amounting to USD 247mn and buyback of USD 85mn) • Generated free cash flow of USD 98mn during the quarter • Basic & Diluted EPS stood at INR 17.86 per share AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.” Operati onal Performance (Consolidated) ₹ Cr Q1FY27 Q1FY26 YoY (%) Q4FY26 QoQ (%) USA 3,770 3,488 8.1% 3,543 6.4% Europe 2,937 2,338 25.6% 2,795 5.1% Growth Markets* 1,063 772 37.7% 980 8.5% ARV 330 355 -6.9% 328 0.8% Total Formulations 8,101 6,953 16.5% 7,646 6.0% Beta-lactam 800 636 25.7% 918 -12.9% Non Beta-lactam 250 279 -10.6% 290 -13.8% Total API 1,049 916 14.6% 1,208 -13.1% Revenue from Operations 9,150 7,868 16.3% 8,853 3.4% *Includes domestic sales of INR 104 Cr in Q1FY27 against INR 75 Cr in Q4FY26 Q1FY27: Consolidated Revenue Breakup - Geography & Business Wise Q1FY27 API, 11.5% US, 41.2% Domestic, 9% ARV, 3.6% Growth Markets, 11.6% International, Europe, 91% 32.1% AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India FoQr1mFuYl2a7ti:o Bnsu siness Area Wise Performance Formulations revenue increased by 16.5% YoY to INR 8,101 Cr. US Formulations • US revenue increased by 8.1% YoY to INR 3,770 Cr primarily driven by volume gains and new launches, partially offset by no transient product sales • As on 30-Jun-26, on a cumulative basis, the company has filed 896 ANDAs with USFDA and has received 737 final approvals and 33 tentative approvals • Launched 10 products during the quarter Europe Formulations • Europe revenue increased by 25.6% YoY to INR 2,937 Cr, driven by robust performance across all key markets; and accounted for 32.1% of consolidated revenue • In euro terms, revenue increased by 11.0% YoY to EUR 267 million Growth Markets Formulations • Growth Markets formulations revenue increased by 37.7% YoY to INR 1,063 Cr, driven by strong performance across key markets; and accounted for 11.6% of consolidated revenue • In USD terms, revenue increased by 25.0% YoY to USD 113 million • Domestic sales for the quarter stood at INR 104 Cr ARV Formulations • ARV business revenue remained broadly stable at INR 330 Cr with QoQ variation driven by tender opportunities, accounting for 3.6% of consolidated revenue • In USD terms, revenue decreased by 2.5% QoQ to USD 35 million Active Pharmaceutical Ingredients (API) • API revenues increased 14.6% YoY, despite sequential seasonal softness in the antibiotics portfolio, and contributed 11.5% of consolidated revenue • In USD terms, revenue increased by 3.7% YoY to USD 111 million AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Q1FY27: Final USFDA Approvals Received Aurobindo Pharma Limited # Product Strength Therapy Area 1 Canagliflozin Tablets (FTF) 100 mg and 300 mg ANTI-DIABETIC 2 Pirfenidone Capsules (FTF) 267 mg ANTIFIBROTIC AGENT 3 Eluxadoline Tablets (FTF) 75 mg and 100 mg ANTI-DIARRHEAL 125 mg/ 5 mL and 250 mg/5 4 Cephalexin for Oral Suspension USP ANTI-INFECTIVE Dextromethorphan Polistirex Extended-Release 5 30 mg/5 mL RESPIRATORY DRUGS Oral Suspension (OTC) 6 Icosapent Ethyl Capsules 1 gram CARDIO VASCULAR DRUGS 7 Dapagliflozin Tablets (FTF)^^ 5mg and 10mg ANTI-DIABETIC 5 mg/500 mg, 5 mg/1000 mg, Dapagliflozin and Metformin Hydrochloride 8 10 mg/500 mg and 10 ANTI-DIABETIC Extended-Release Tablets (FTF)^^ mg/1000 mg 9 Tofacitinib Tablets^^ 5mg and 10mg PAIN RELIEF DRUGS 10 Glycerol Phenylbutyrate Oral Liquid^^ 1.1 grams per mL NITROGEN-BINDING AGENT ^^ Received Tentative approval earlier now received Final approval Q1FY27: Earnings Call Details The company will host earnings call at 8.30 AM IST on 06-Aug-26, to discuss the performance and answer any questions from participants. To join the call through Zoom, please pre-register using the link: https://bit.ly/4gVr1CV AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India About Aurobindo Pharma Limited Au robindo Pharma Limited (www.aurobindo.com) , (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients g [Showing first 8,000 characters — download PDF for full document]